Navigation Links
Avalere Health Data Finds Four-Tier System Growing Among Medicare Part D Plans

WASHINGTON, April 15 /PRNewswire/ -- Avalere Health today reminded consumers to pay close attention to all aspects of their Medicare prescription drug plan, including on which "tier" or group their medications are covered. Avalere data released from its proprietary DataFrame(R) database show that an overwhelming majority of Medicare health plans are now using a system that places some of the most expensive drugs in newly created fourth and fifth tiers. Drugs in the higher tiers can cost consumers significantly more money than a three tier, fixed co-payment system.

Consumers traditionally pay fixed amounts, or co-pays, when purchasing prescription drugs, and these co-pays are typically lumped into three groups: generics, preferred brands, and non-preferred brands. However, Medicare Part D drug plans have revolutionized the shape of the market by placing more expensive drugs into additional tiers. According to Avalere, 86% of all Medicare Part D plans use four (and sometimes five) tier plan structures, versus only 10% of commercial health plans.

"Health plans are trying to balance competing demands of access to medications and low cost, but the result is that patients with serious illnesses are paying more," said Dan Mendelson, president of Avalere Health. "It's a trend that's starting to push into the commercial world too."

Using its proprietary DataFrame database, which houses information about every Medicare drug plans' drug coverage and associated benefits, found that on average, Medicare Part D beneficiaries pay 25 percent to 35 percent of the cost of Tier 4 drugs compared with commercial plan beneficiaries who pay a fixed fee of about $71. Specialty drugs found in Tier 4 formularies can cost in excess of $600 per month.

"People with cancer, multiple sclerosis, hepatitis C, rheumatoid arthritis, and anemia should be paying very close attention to tiering in Medicare," said Mendelson.

Other facts released by Avalere:

-- Among Medicare's top 10 Part D plans, 9 use Tier 4 formularies;

-- The average co-payment for 4th Tier drugs in the Medicare community is


-- The average co-payment for 3rd Tier or non-preferred drugs in the

Medicare community is $40;

-- Medicare patients generally pay about $20 for preferred prescriptions,

and $10 for generic drugs.

For graphics you can use for media stories, please contact Kim Coghill at For more information about Avalere's DataFrame database and the Medicare marketplace, contact Brian Bruen at

SOURCE Avalere Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the Donut Hole
2. Texas Health Care Association: New Report on Long Term Care Workforce Spotlights Need to Boost Texas Medicaid Rates
3. Lake Hospital System Selected as Pilot Site for Health Information Literacy Research Project
4. New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements
5. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
6. Health Monitoring Systems Releases EpiCenter(TM)
7. Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008
8. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
9. Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief
10. Healthy Diabetic Bakery Products Launched Nationally
11. PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements
Post Your Comments:
(Date:11/29/2015)... ... November 30, 2015 , ... The Cyber Monday deal is a deep 40% or ... right time to get gifts for the skin care lover in your circle. Each ... serums . This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , ...
(Date:11/29/2015)... ... 29, 2015 , ... ProStatic Analog Distortion from Pixel Film ... for Final Cut Pro X. FCPX users can now apply distortion ... Destoying and creating chaotic distortion is now quick and simple, putting film makers ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 6th by ... University of British Columbia suggested that laws requiring bicyclists to wear helmets may not ... of the reason for the controversial conclusion is that, while helmets have certainly prevented ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... 2015   National Decision Support Company (NDSC) continues ... including notable statewide implementations. As a result, ordering ... Select, more than 1 million times per month—all ... Select provides real-time feedback on the most appropriate ... been implemented at over 100 healthcare systems nationally, ...
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
Breaking Medicine Technology: